#Immunotherapeutics for #hememalignancy. Stem cell mobilization. #CARTcell #GvHD #CRISPR #CytokineReleaseSyndrome @wustlmed @sitemancenter
Joined January 2021
- Tweets58
- Following13
- Followers588
- Likes24
DiPersio’s Altered Career Path Led to Groundbreaking Developments in Leukemia onclive.com/view/dipersio-s-… via @onclive
DiPersio recognized for discoveries in cancer biology source.wustl.edu/2022/11/dip…
Check out my podcast on vjhemonc!
vjhemonc.com/podcast/car-t-t…
Congratulations, Steve, on the final publication. You took the lead on this project and I, like you, hope it will have a transformative effect on improving the safety of patient transplants in the future.
This Post is from an account that no longer exists. Learn more
A summary of the new developments in treating #GVHD discussed at #ASH21.
vjhemonc.com/video/tx-x31kr3…
More hope for preventing chronic #GvHD! Small prophylactic trial in patients using belimumab, an antibody against BAFF, to keep from activating the B cells. Early results suggest it may help!
vjhemonc.com/video/8ckxvo-gl…
Mobilizing stem cells in #myeloma patients with motixafortide (BL8040).
#hememalignancies
vjhemonc.com/video/pf60frowc…
ASH! Using Jak-inhibitors to prevent #GvHD in patients. Low #CRS. Good anti-leukemic effect.
vjhemonc.com/video/ei4a1b2lh…
Indeed! Good news for our patients and scientists!
It's official! Wonderful news that we'll be expanding the BTCF/GMP to develop novel therapies, including cellular therapies! @WUSTLmed @SitemanCenter
School of Medicine to expand Lipstein BJC Institute of Health building medicine.wustl.edu/news/scho… via @wustlmed
Agree! Good team. Good work.
Congrats to Jeff Ward, Nancy Bartlett, and the whole @WUSTLmed @SitemanCenter team! Promising new combination for rel/ref DLBCL. Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory DLBCL #lymphoma pubmed.ncbi.nlm.nih.gov/3478…
John F. DiPersio Lab retweeted
The Pachynski Lab is looking to hire!
Leukocyte trafficking, tumor immunology, and basic/translational projects with a focus on prostate cancer.
Please RT!
sites.wustl.edu/pachynskilab…
#postdocjobs @PCF_Science @WUSTLdbbs @WUSTLImmuno @ACS_Research @WUSTLmed
Welcoming Jingyu Xiang to the lab today! Jerry has the distinction of publishing with us in September before he even joined! Welcome Jerry!
Wanted: level two technicians to work on immunological approaches to cure blood cancers (#myeloma #leukemia) at Washington University in St. Louis. General lab and animal handling experienced preferred. Email: [email protected] #sciencejobs #CARTcells
#CARTcell targeting CD7 could significantly decrease a patient’s immune function. Our recent preclinical work led by Dr. Miriam Kim shows that a transplant of hematopoietic stem cells with CD7 #CRISPR’d out could solve that problem. insight.jci.org/articles/vie…
John F. DiPersio Lab retweeted
Amazing opportunities to develop cutting edge #neoantigen vaccine trials (@GavinGpdunn @LabFehniger @Pachynski_Lab @malachigriffith @chrisamiller), #ctdna studies (@aadel_chaudhuri @ChrisMaher_Lab) and novel #ProstateCancer treatments (@MReimersMD @uropro)!
Want to know what we are up to @SitemanCenter in St. Louis?
@WUSTLmed @WUDeptMedicine @WashUHeme @RPachynski @mpndoc @dgermain21
siteman.wustl.edu/wp-content…
John F. DiPersio Lab retweeted
Siteman has been ranked No. 1 in Missouri, No. 1 in St. Louis and among the top 1% of cancer centers nationally by U.S. News & World Report.
Learn more: ow.ly/1EVL50FEYP6.
